Evidence map›Paper›PMID 18844996›Full record

ArticleBMC microbiology2008

Development and application of the active surveillance of pathogens microarray to monitor bacterial gene flux.

Richard A Stabler, Lisa F Dawson, Petra C F Oyston, Richard W Titball, Jim Wade, Jason Hinds, Adam A Witney, Brendan W Wren

Abstract readEvaluation Study
In one paragraph

Article in BMC microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richard A StablerDepartment of Infectious and Tropical Diseases, Keppel Street, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK. richard.stabler@lshtm.ac.uk
Lisa F Dawson
Petra C F Oyston
Richard W Titball
Jim Wade
Jason Hinds
Adam A Witney
Brendan W Wren

Funding

Medical Research Council G0300020Wellcome Trust 062511
6 · The paper itself

Abstract

backgroundHuman and animal health is constantly under threat by emerging pathogens that have recently acquired genetic determinants that enhance their survival, transmissibility and virulence. We describe the construction and development of an Active Surveillance of Pathogens (ASP) oligonucleotide microarray, designed to 'actively survey' the genome of a given bacterial pathogen for virulence-associated genes.

resultsThe microarray consists of 4958 reporters from 151 bacterial species and include genes for the identification of individual bacterial species as well as mobile genetic elements (transposons, plasmid and phage), virulence genes and antibiotic resistance genes. The ASP microarray was validated with nineteen bacterial pathogens species, including Francisella tularensis, Clostridium difficile, Staphylococcus aureus, Enterococcus faecium and Stenotrophomonas maltophilia. The ASP microarray identified these bacteria, and provided information on potential antibiotic resistance (eg sufamethoxazole resistance and sulfonamide resistance) and virulence determinants including genes likely to be acquired by horizontal gene transfer (e.g. an alpha-haemolysin).

conclusionThe ASP microarray has potential in the clinic as a diagnostic tool, as a research tool for both known and emerging pathogens, and as an early warning system for pathogenic bacteria that have been recently modified either naturally or deliberately.

Indexed as

BacteriaBacterial InfectionsBacterial ProteinsDNA, BacterialDrug Resistance, BacterialHumansOligonucleotide Array Sequence AnalysisVirulenceVirulence FactorsBacterial ProteinsDNA, BacterialVirulence Factors

Identifiers

PMID18844996
PMCPMC2607285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.